Vyome Posts Q2 Loss, FDA Feedback on VT-1953, and JAK Inhibitor Deal
HIND sits 29% above its 52-week low of $1.75 on light trading volume (0.2× avg).
Summary
Vyome reported Q2 2026 results with a net loss of $720K and cash of $7.9M, down from $8.8M at Q1 end. The company received FDA written feedback on its VT-1953 pivotal trial strategy and plans a Type C meeting. It also in-licensed two selective JAK inhibitors from Impetis and secured a Chinese patent for VB-1953. The balance sheet remains clean with no debt or preferred stock. The FDA feedback is a key regulatory milestone for the lead program, and the Impetis deal broadens the pipeline. Watch for the Type C meeting outcome and any update on the Indian tax demand.
At the time of this announcement, HIND was trading at $2.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.7M. The 52-week trading range was $1.75 to $12.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.